Efanesoctocog alfa not checked

Swedish Orphan Biovitrum · BIVV001

FollowEvery change as it happens, and a Monday email
Stage
in the EU and EU
Next date
Phase 3 trial completes
Trials
4 active
6 in total · 6 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participant in this study must be prescribed efanesoctocog alfa prophylactic treatment per their standard of care from their physician. No drug will be provided by the Sponsor.”In the company’s words, NCT06940830 on ClinicalTrials.gov
Tested for
Haemophilia A (Moderate or Severe) (2 trials), Hemophilia, Classic, Haemophilia, Hemophilia, Classic Hemophilia, Synovial Hypertrophy, Hemophilia A
Main trialPhase 4
“The rationale for conducting this open-label phase 4 study is to assess whether once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) improves the disease course of existing synovial hypertrophy and prevents the risk of joint bleeds in patients with moderate or severe haemophilia A. The use of imaging assessments will allow for objective detection and monitoring of synovial hypertrophy, and thus expand on the previous findings demonstrating positive effects of once-weekly prophylaxis with efanesoctocog alfa (50 IU/kg) on joint health.”In the company’s words, NCT06752850 on ClinicalTrials.gov
Other names
BIVV001 · Altuvoct · Altuviiio

Other drugs for Haemophilia A (Moderate or Severe)

All 26 drugs for Haemophilia A (Moderate or Severe)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 17 Nov 2026 A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
Phase 4Active, not recruiting Dec 2028 Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa
Phase 3Active, not recruiting Mar 2027 Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa
Phase 3Completed 2 Jun 2026 A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
Phase 1Completed 21 May 2026 Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
Phase 3Authorised not given Efanesoctocog alfa treatment in patients with synovitis in congenital hemophilia A: multicenter, randomized, open-label, phase 3 clinical trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Efanesoctocog alfa

Following is part of Solo: you see every change to Efanesoctocog alfa the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in